In December 2025, Tenaya closed a financing that generated $55.8 million net proceeds and structured a multi-target research collaboration with Alnylam that includes an upfront payment, collectively extending its operating runway into the second half of 2027.

The MyPEAK™-1 Phase 1b/2 trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy reported no dose-limiting toxicities at 3 × 10¹³ and 6 × 10¹³ vector genomes per kilogram doses, with increases in MyBP-C protein and improved New York Heart Association Class I status in all patients. The company plans expanded enrollment, interim data readouts and regulatory alignment milestones throughout 2026.

In the RIDGE™-1 Phase 1b/2 trial, TN-401 showed an acceptable safety profile at 3 × 10¹³ vg/kg with robust PKP2 transduction, a 10 percent average protein increase and meaningful reductions in ventricular arrhythmias. The data and safety monitoring board endorsed continued enrollment in expansion cohorts, with further safety and efficacy data expected in 2026.

Preclinical data for TN-301, a selective HDAC6 inhibitor, demonstrated potential in Duchenne muscular dystrophy models, supporting broader cardiac indications. The newly formed Alnylam collaboration validates Tenaya’s platform and will advance TN-301 toward clinical development with external funding support.